🔬 Loss of CDK12 drives aggressive #ProstateCancer progression and opens new therapeutic avenues! 🧬
Key findings:
CDK12 loss promotes transcription-replication conflicts, DNA damage, and immune infiltration.
CDK13 degradation (via the PROTAC YJ1206) shows promise as a targeted therapy.
Dual CDK12/AKT inhibition effectively reduces tumor growth in preclinical models.
🚀 Future: Advancing CDK12/13 degraders for clinical trials in advanced prostate cancer.
#ReadMore >@ArulChinnaiyan
#ProstateCancer